Navigation Links
Chemo Combo Shows Promise Against Ovarian Cancer
Date:4/19/2009

Lab-based study focused on certain types of malignancies

SUNDAY, April 19 (HealthDay News) -- Adding the drug dasatinib to a standard, two-drug chemotherapy regimen for treating ovarian cancer boosted the effectiveness of the drugs in laboratory tests, new research shows.

Researchers at the Duke Comprehensive Cancer Center added dasatinib, along with carboplatin and paclitaxel, to four types of ovarian cancer cells.

In some types of ovarian cancers, a pathway called SRC is involved in the abnormal cell proliferation, said Dr. Deanna Teoh, a fellow in gynecologic oncology at Duke and lead investigator on this study.

"By examining gene expression data, we determined that the combination of the leukemia drug dasatinib (Sprycel) made carboplatin and paclitaxel more effective in cell lines with higher levels of SRC expression and SRC pathway deregulation," Teoh said.

Dasatinib, which is marketed by Bristol-Meyers Squibb under the brand name Sprycel, is FDA-approved for treating leukemia.

"These findings indicate that we may be able to direct the use of a targeted therapy like dasatinib based on gene expression pathways in select ovarian cancers," she said.

The results of the study were to be presented Sunday at the American Association for Cancer Research annual meeting, in Denver.

Researchers examined four ovarian cancer cell lines, known as IGROV1, SKOV3, OVCAR3 and A2780. Three of the cell lines demonstrated high activation of SRC, and one demonstrated lower SRC expression. All were treated in lab dishes with various combinations of the chemotherapy drugs dasatinib, carboplatin and paclitaxel.

"We found that the addition of dasatinib to standard therapy in the three cell lines with significant SRC pathway deregulation -- IGROV1, OVCAR3 and A2780 -- enhanced the response of the cancer cells to therapy," Teoh said. "Conversely, in SKOV3, which has minimal SRC protein expression and pathway deregulation, we saw the least amount of anti-cancer activity when we added dasatinib."

The results of the study support further investigation of targeted biologic therapy using a SRC inhibitor in some ovarian cancers, Teoh said. Currently a phase 1 trial of a combination of dasatinib, paclitaxel and carboplatin is available for women with advanced or recurrent ovarian, tubal and peritoneal cancers, the researchers said.

More information

The American Cancer Society has more on ovarian cancer.



-- Jennifer Thomas



SOURCE: Duke Comprehensive Cancer Center news release, April 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Chemotherapy may be culprit for fatigue in breast cancer survivors
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. To evade chemotherapy, some cancer cells mimic stem cells
4. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
5. PET scans can accurately detect a breast tumors response to chemotherapy
6. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
7. New Software Program Helps Breast Cancer Survivors and Patients Fight Chemofog
8. Medicare modernization act did not change chemotherapy as feared
9. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
10. Cancer conflict with chemotherapy treatment
11. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s National Health System ... (AHA) to launch a Rheumatic Heart Disease Center, with the goal of developing ... heart disease (RHD) in high-risk, financially disadvantaged countries and low-income communities across the ...
(Date:6/22/2017)... California (PRWEB) , ... June 22, 2017 , ... A ... Nira Rittenberg to a correspondent concerned about an apparent lack of oral hygiene by ... who specializes in geriatrics and dementia-related matters, suggests a number of steps, including scheduling ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... organization, announces recipients of its annual “UBBIE” Awards (pronounced you-bee) for 2017. ... demonstrated significant achievements toward their involvement with UBA, the clients they serve, and ...
(Date:6/20/2017)... PA (PRWEB) , ... June 20, 2017 , ... Fresenius ... specialize in minimally invasive techniques to treat and manage a wide range of vascular ... strategic rebranding initiative. With more than 65 centers represented by more than 40 local ...
(Date:6/20/2017)... York, NY (PRWEB) , ... June 20, 2017 , ... ... today their continued expansion and success in the clinical trials market. Similar to its ... a track record in the clinical trials marketplace by proving the value of eVisits ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... Infusion Group, a brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has ... location. The Iowa facility ... cleanroom—the standard needed to compound intravenous (IV) nutrition formulations. A cleanroom ... "Our new cleanroom will allow us ... Iowa patients," said Phil Rielly , Diplomat ...
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
(Date:5/26/2017)...  Endo International plc (NASDAQ: ENDP ) announced ... represent the Company in a fireside chat at Goldman Sachs, ... 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ET. ... Rancho Palos Verdes, CA. A ... available on the Company,s website at http://www.endo.com/investors/overview . Participants ...
Breaking Medicine Technology: